Mdm2-null and Mdm4-null mice are embryonic lethal {#mjx004s1}
=================================================

Mdm2 (murine double minute 2) and its homologue, Mdm4 (also referred to as MdmX), are two major negative regulators of the tumour suppressor p53 (Figure [1](#mjx004F1){ref-type="fig"})([@mjx004C26]). Both proteins contain RING finger domains at their respective C-termini. The RING domain of Mdm2 harbours E3 ligase activity, giving it the ability to initiate p53 degradation, Mdm4 degradation, and degradation of itself. Although the RING domain of Mdm4 is not enzymatically active, both Mdm2 and Mdm4 bind to the N-terminal transcriptional activation domain of p53 and repress the transcriptional activity of p53 in homoeostasis. Furthermore, p53 and Mdm2 are involved in a negative feedback loop; p53 transactivates *Mdm2* and Mdm2 in turn targets p53 for proteasomal degradation. Lastly, Mdm2 and Mdm4 form a heterodimer that maximizes inhibition of p53 ([@mjx004C34]; [@mjx004C29]).

![Schematic of the Mdm2, Mdm4, and p53 relationships described in this review. Mdm2 and Mdm4 are negative regulators of p53. Mdm2 also has the ability to ubiquitinate p53, itself, and Mdm4 proteins to target them for proteasomal degradation. p53 signals for the transcription of *Mdm2* when it is needed in the cell. Mdm2 and Mdm4 have the ability to form and function as a heterodimer.](mjx004f01){#mjx004F1}

*Mdm2*-null and *Mdm4*-null mice are embryonic lethal, indicating that Mdm proteins are vital in development. Moreover, these phenotypes can be rescued with concomitant loss of *p53* (*Mdm2*^*−/*^*^−^p53*^*−/−*^ and *Mdm4*^*−/−*^*p53*^*−/−*^ mice are viable), indicating that the lethality is due to activation of p53. The loss of *Mdm2* in an embryo results in death due to a p53-mediated apoptotic mechanism ([@mjx004C15]; [@mjx004C4]; [@mjx004C22]; [@mjx004C27]). This occurs prior to implantation of the embryos at embryonic day 3.5 (E3.5). In contrast, embryos lacking *Mdm4* initiate cell cycle arrest and occasionally apoptosis, but they do so at later developmental timepoints---normally around gastrulation of the embryo (E7.5) ([@mjx004C27]; [@mjx004C21]). The progression of mouse development is shown in Figure [2](#mjx004F2){ref-type="fig"}.

![Illustration of mouse embryos at important embryonic timepoints that are highlighted throughout this review. The shaded area at E9.5 represents the location of the heart, at E14.5 the location of the kidney, and at E17.5 the location of the brain and CNS.](mjx004f02){#mjx004F2}

Due to limitations of studying development in embryonic lethal mouse models, conditional alleles were generated to evaluate the functions of Mdm2 and Mdm4 at later developmental stages and in various tissues of adult mice. In this review, we will explore the research that aims at understanding the roles of Mdm2 and Mdm4 during organogenesis and organ development.

Alterations in intrinsic functions of Mdm proteins lead to accumulation and/or hyperactivity of p53 {#mjx004s2}
===================================================================================================

In attempts to gain a better understanding of the interactions between Mdm2, Mdm4, and p53, multiple mouse models were created that alter the intrinsic functions of Mdm2 or Mdm4 in order to examine their physiological importance. The *Mdm2* gene contains two promoters; a p53-independent promoter (P1), located upstream from the first exon that is constitutively active under basal conditions, and a p53-dependent promoter (P2) residing in the first intron that is only activated in response to DNA damage and stress conditions ([@mjx004C2]). When DNA is damaged, p53 binds to the P2 promoter of *Mdm2*, which leads to increased Mdm2 levels and subsequent decreased p53 levels. [@mjx004C26] generated point mutations in the P2 promoter that disrupt interactions with p53 (*Mdm2*^*P2/P2*^ mice) to examine the significance of the Mdm2-p53 feedback loop (Figure [3](#mjx004F3){ref-type="fig"}A) ([@mjx004C26]). Abrogation of p53 binding at the *Mdm2-P2* promoter does not alter basal levels of Mdm2 or p53, but mice are extremely sensitive to low-dose ionizing radiation (IR). The inability of p53 to upregulate Mdm2 results in extended p53 activity and a p53-dependent death. Another mouse, *Mdm2*^*Y487A/Y487A*^, was generated to specifically examine the importance of Mdm2 E3 ligase activity. A point mutation at amino acid 487 in the C-terminus of Mdm2 disrupts E3 ligase activity yet allows Mdm2 to inhibit p53 and thus results in viable mice. However, as *Mdm2*^*P2/P2*^ mice, *Mdm2*^*Y487A/Y487A*^ mice are sensitive to IR ([@mjx004C31]). These differences in viability showcase the lower levels of Mdm2 and/or Mdm4 activity required for homoeostasis. A mouse with a mutation at amino acid 462 of Mdm2 that disrupts both E3 ligase function and interactions with Mdm4, *Mdm2*^*C462A/C462A*^, is lethal because of too much p53 activity ([@mjx004C14]). Other studies with specific deletion of the *Mdm4* RING domain that removes interactions with Mdm2 (*Mdm4*^*ΔRING/ΔRING*^) and a point mutation in *Mdm4* that also disrupts interactions with Mdm2 (*Mdm4*^*C462A/C462A*^) are embryonic lethal (Figure [3](#mjx004F3){ref-type="fig"}B) ([@mjx004C13]; [@mjx004C25]). Again these phenotypes are rescued by *p53* loss (*Mdm4*^*ΔRING/ΔRING*^*p53*^*−/−*^ and *Mdm4*^*C462A/C462A*^*p53*^*−/−*^, respectively). Thus, interactions between the RING domains of Mdm2 and Mdm4 are vital for sufficient Mdm activity to inhibit p53 during early development.

![Generated alleles of *Mdm2* or *Mdm4* (*MdmX*). Exons are depicted by black boxes marked with the appropriate number. (**A**) The wild-type (WT) allele of *Mdm2* is shown. The null allele contains a neomycin cassette inserted in place of exons 10--12. The *Mdm*^*flox*^ allele creates a conditionally null allele by flanking exons 7 through 9 with *loxP* sites. These exons will be removed after Cre-mediated recombination of the *loxP* sites. *Mdm2*^*FM*^ is generated using *loxP* sites surrounding exons 5 and 6, which encodes the p53 interaction domain. The *Mdm2*^puro/Δ7--12^ allele retains the puromycin cassette in intron 6. The PND (mutant P2 promoter, neomycin cassette, and 184-bp deletion) allele has a 184-bp deletion in intron 3 in conjunction with retention of the neomycin cassette and deletion of the p53 response elements present in the *Mdm2*^*P2/P2*^, a knock-in mouse harbouring mutation of the p53-binding sequences in the *Mdm2-P2* promoter, allowing for basal Mdm2 expression. The *Mdm2*^*Y487A*^ allele contains a point mutation at amino acid number 487. This knock-in mutation converts a Tyrosine to an Alanine thus disrupting the E3 ligase activity of the Mdm2 RING domain but still allowing it to bind to Mdm4. The *Mdm2*^*C462A*^ allele contains a point mutation at amino acid number 462. This knock-in mutation converts a Cysteine to an Alanine thus removing E3 ligase and disrupting interactions with Mdm4. (**B**) The WT allele of *Mdm4* is shown. The original *Mdm4-*null allele has a neomycin cassette in place of exons 3 and 4 removing the majority of the p53-binding domain. This allele creates a small C-terminal protein that retains interactions with Mdm2. The *Mdm4*^*Δ2*^ deletes exon 2. The *Mdm4*^*Δ2*^ allele is a true null. The *Mdm4*^*FX*^ allele is generated using a floxed exon 2. Through Cre recombination, this exon can be conditionally removed. Exon 2 of *Mdm4* (*MdmX*) is the first coding exon and its loss results in a functionally null allele. The *Mdm4*^*ΔRING*^ allele contains an in-frame deletion of the RING domain within exon 11 composed of 49 amino acids. The *Mdm4*^*C462A*^ allele contains a neomycin-resistant gene cassette in intron 10 and a point mutation at amino acid number 462 within exon 11, making it unable to form a heterodimer with Mdm2.](mjx004f03){#mjx004F3}

Loss of Mdm2 and Mdm4 in the central nervous system {#mjx004s3}
===================================================

Given that radiation of embryos displays a very strong p53-dependent effect within the central nervous system (CNS), Mdm2 and Mdm4 are also implicated in nervous system development. Thus, [@mjx004C36] used a neuron-specific transgenic Cre, *Nestin-Cre* (*Nes-Cre*), to delete *Mdm2* and *Mdm4* within the CNS to explore any redundancies that these two genes may play in the development of the CNS (Table [1](#mjx004TB1){ref-type="table"}). *Mdm2*^*FM/FM*^ or *Mdm4*^*FX/FX*^ (conditional alleles of *Mdm2* or *Mdm4*, respectively) mice were crossed to *Mdm2*^*FM/+*^*Nes-Cre* or *Mdm4*^*FX/+*^*Nes-Cre* mice, respectively (Figure [3](#mjx004F3){ref-type="fig"}) ([@mjx004C10]). The neuron-specific enhancer of the *Nestin* promoter drives Cre expression and recombination in the neurons and glia begins at E10.5 ([@mjx004C9]). At weaning, no *Mdm2*^*FM/FM*^*Nes-Cre* mice are obtained. Occasionally, mice are born with abnormally shaped heads; however, they die very soon after birth. Phenotypic defects due to the loss of *Mdm2* include a domed-head phenotype, decreased neuronal tissue, thinner cerebral cortexes, and excess cerebrospinal fluid in the brain observed as early as E12.5. At E18.5, *Mdm2*^*FM/FM*^*Nes-Cre* embryos have virtually no neuronal tissue remaining and are unable to survive until time of birth. Table 1Synopsis of the different drivers of the Cre-recombinase system utilized within the discussed works.TypeDriverSite of expressionExpression initiationCited works*αHoxb7*-CreTransgenic*Homeobox B7*Ureteric bud and mesonephric ductE9.5[@mjx004C11]*αMyHC*-CreTransgenic*α-myosin heavy chain*CardiomyocytesE8.5[@mjx004C23], [@mjx004C1], [@mjx004C35]CAG-CreERTransgenic*CMV* enhancer/chicken β-actinUbiquitous expressionTamoxifen-inducible[@mjx004C38]Le-CreTransgenic*Pax6*Surface ectoderm, retinal, and pancreatic primordial cellsE9[@mjx004C39]*Nes*-CreTransgenic*Nestin*Central and peripheral nervous systemsE10.5[@mjx004C9], [@mjx004C7], [@mjx004C10], [@mjx004C36]*SM22*-CreKnock-in*Smooth muscle protein 22-α* geneVascular and visceral smooth muscle cells of adult miceTamoxifen-inducible[@mjx004C17], [@mjx004C3]*Tie2*-Cre *(*Tek-*Cre)*Transgenic*Tek receptor Tyrosine kinase*Endothelial cellsE7.5[@mjx004C16], [@mjx004C37]*Villin*-CreTransgenic*Villin 1*Epithelial cells of small and large intestinesE9[@mjx004C5], [@mjx004C19], [@mjx004C33], [@mjx004C32]*Zp3*-CreTransgenic*Zona Pellucida 3*Growing oocytesBefore first meiotic division[@mjx004C6], [@mjx004C18][^1]

The same experiments are performed on the *Mdm4* CNS-specific deletion mice ([@mjx004C36]). No *Mdm4*^*FX/FX*^*Nes-Cre* mice are observed at birth. Embryonically, they do not begin to show any phenotypic defects until E17.5, at which time, they display a flat head resulting from a large cavity that developed within the brain. This phenotype increases in severity through E18.5. Deletion of both *Mdm2* and *Mdm4* led to more severe phenotypes. These results indicate that Mdm2 and Mdm4 are essential for the development of the CNS, although the phenotypes of *Mdm2* loss are more dramatic and present at an earlier embryonic timepoint.

Further experiments utilizing these mice indicate that *Mdm2* as well as *Mdm4* CNS-specific deletions ultimately lead to both apoptosis and cell cycle arrest within these tissues. However, *Mdm2*^*FM/FM*^*Nes-Cre* mice show an increase in p53 4 days before *Mdm4*^*FX/FX*^*Nes-Cre* mice do so (E10.5 and E14.5, respectively) resulting in death. Additionally, crosses with *p53*^*−*/−^ mice show that these lethal phenotypes are p53-dependent, verifying that Mdm2 and Mdm4 are indispensable regulators of p53 during the development of the CNS.

[@mjx004C7] conducted a similar study in which they used *Mdm2* and *Mdm4-*null mice in conjunction with *Nes-Cre* and the *p53*^*LSL/LSL*^ allele. Upstream of the normal coding region of *p53*, the *p53*^*LSL/LSL*^ allele has a transcriptional stop element surrounded by *loxP* sites. In the absence of tamoxifen, no p53 protein is produced from this allele. However, upon administration of tamoxifen, the *loxP* sites recombine and remove the stop element, allowing for the production of a functional wild-type (WT) p53 protein. Analyses of individual deletions (*p53*^*LSL/−*^*Mdm2*^*−/−*^*Nes-Cre* and *p53*^*LSL/−*^*Mdm4*^*−/−*^*Nes-Cre* mice) show analogous results to the aforementioned study. Moreover, this group also examined *Mdm2;Mdm4* double null (*p53*^*LSL/−*^*Mdm2*^*−/−*^*Mdm4*^*−/−*^*Nes-Cre*) mice. Surprisingly, all observed phenotypes are intensified in these double knockout mice and are p53-dependent. Morphologically, these mice have the smallest heads and the least amount of neuronal tissue at E14.5. Additionally, these *p53*^*LSL/−*^*Mdm2*^*−/−*^*Mdm4*^*−/−*^*Nes-Cre* mice exhibit less cycling cells coupled with extremely high apoptosis and p53 stabilization. Since the phenotype of double knockout mice is worse than either single knockout, these data suggest that Mdm2 and Mdm4 play non-overlapping and important roles when regulating p53 in the CNS.

Mdm2 and Mdm4 trade off to support cardiomyocyte maintenance {#mjx004s4}
============================================================

Due to the fact that apoptosis and proliferation are key processes in heart development, tissue-specific Cre systems were used to delete *Mdm2* and *Mdm4* in the heart ([@mjx004C15]; [@mjx004C35]). The αMyHC-Cre transgene is under control of the α-myosin heavy chain promoter, which is specific to cardiomyocytes and is expressed early in cardiogenesis at E8.5 (cardiogenesis is initiated at E7.5) ([@mjx004C23]; [@mjx004C1]). No mice survived with complete loss of *Mdm2* in the heart. Results indicate that all *Mdm2*^*FM/−*^αMyHC-Cre mice die by E13.5. Defects can be seen starting at E9.5, an embryonic day later than the initiation of Cre expression. At this time, the walls of the heart are much thinner than normal and, if able to develop further, at E13.5 the heart does not function properly resulting in blood leakage from the ventricles. The deficiencies seen within these embryos ultimately lead to heart failure and death prior to birth. Further analysis reveals that these phenotypic changes are due to apoptosis arising in conjunction with low levels of proliferation among the few remaining cardiomyocytes. The loss of *Mdm2* specifically in the heart cells (*Mdm2*^*FM/−*^αMyHC-Cre) results in embryonic death due to the activation of p53, disrupting the delicate pattern of proliferation and apoptosis necessary for the developing heart. Concomitant loss of *p53* leads to viable *p53*^*−/−*^*Mdm2*^*FM/−*^αMyHC-Cre mice with the same lifespan as *p53*^*−/−*^ and *p53*^*−/−*^*Mdm2*^*−/−*^ mice. Thus, the lethal phenotype is p53-dependent.

The same study found that loss of *Mdm4* (*Mdm4*^*FX/*Δ2^αMyHC-Cre---*Mdm4*^Δ2^ is a null allele) specifically in cardiomyocytes does not result in embryonic lethality ([@mjx004C10]). *Mdm4*^*FX/*Δ2^αMyHC-Cre mice appear to be phenotypically and developmentally normal. Thus, *Mdm2* but not *Mdm4* is required for the proper development of the heart. However, abnormalities in the *Mdm4*^*FX/*Δ2^αMyHC-Cre mice become noticeable as early as 3 months. By 8 months of age, the functional defects of the heart are apparent. Mice are swollen, have decreased mobility, and display shortness of breath. By 8 months, *Mdm4*^*FX/*Δ2^αMyHC-Cre mice have half the number of cardiomyocytes. TUNEL staining reveals that this is a result of apoptosis coupled with an expected lack of proliferation. All of these mice die within a year, giving them a significantly decreased lifespan compared to controls. [@mjx004C35] noted that *Mdm4*^*FX/*Δ2^αMyHC-Cre mice die of dilated cardiomyopathy, a leading cause of heart failure with few genes being implicated in its heredity. Further analyses reveal that all chambers of the heart are dilated with thinner ventricle walls compared with controls. Additionally, fibrosis is present in the *Mdm4*^*FX/*Δ2^αMyHC-Cre hearts, which ultimately leads to heart failure. Moreover, *Mdm4*^*FX/*Δ2^αMyHC-Cre male mice die significantly earlier than females, which is consistent with human cardiomyopathy data. All of these phenotypes are rescued by loss of *p53*. These experiments indicate that Mdm2 and Mdm4 have critical roles to play in the development and homoeostasis of murine hearts. While Mdm2 trumps organogenesis of this tissue, Mdm4 is fundamental in maintaining regulation of p53 in adult cardiomyocytes.

[@mjx004C37] orchestrated a similar study in which they used *Tie2-Cre* to evaluate *Mdm* loss specifically during cardiac endocardial cushion morphogenesis. The *Tie2-Cre* is under the control of the mouse endothelial-specific receptor tyrosine kinase promoter (*Tie2* or *Tek*) and is expressed beginning at E7.5 ([@mjx004C16]). Much like the aforementioned study, the *Mdm2*^*FM/FM*^*Tie2-Cre* mice die before E10.5 due to a misshapen developing heart and severe vascular defects throughout their bodies. The p53 target genes *p21* and *Puma* are significantly upregulated in the hearts of these mice. This group also evaluated *Mdm2*^*FM/+*^*Mdm4*^*+/*Δ2^*Tie2-Cre* mice in order to determine whether loss of only one allele of *Mdm2* in conjunction with loss of one allele of *Mdm4* would produce different results than loss of both copies of *Mdm2* (*Mdm2*^*FM/FM*^*Tie2-Cre*). *Mdm2*^*FM/+*^*Mdm4*^*+/*Δ2^*Tie2-Cre* mice are viable yet the majority die within the first 2 weeks after birth with all mice dying by 8 weeks. The majority of *Mdm2*^*FM/+*^*Mdm4*^*+/*Δ2^*Tie2-Cre* mice did not achieve closure of their atrial or ventricular septum leading to significant decreases in heart function and arrhythmias. Thus, haploinsufficiency of *Mdm2* and *Mdm4* in the endothelial cells of mice leads to heart malfunctions detrimental enough to lead to postnatal death. Additionally, the phenotypic defects of these *Mdm2*^*FM/+*^*Mdm4*^*+/*Δ2^*Tie2-Cre* mice can be rescued with deletion of one copy of *p53* (*p53*^*−/−*^*Mdm2*^*FM/+*^*Mdm4*^*+/*Δ2^*Tie2-Cre*).

Mdm2 is vital for the development of fully functioning kidneys {#mjx004s5}
==============================================================

The majority of kidney failure cases are linked to developmental defects in proper ureteric bud formation. This process is directly affected by choreographed cell death and proliferation. Studies in mice with low amounts of *Mdm2* or *Mdm4* reveal small and poorly functioning kidneys ([@mjx004C30]), suggesting that p53 levels may impact normal kidney function. An intricate spatial relationship between *Mdm2* and *p53* exists during kidney development, with both genes being highly expressed in the kidney early in embryogenesis and then slowly declining during the remainder of development. *Mdm2* was deleted specifically in the ureteric bud lineage using *αHoxb7-Cre* transgene in conjunction with the *Mdm2*^*flox*^ allele, resulting in a functionally null *Mdm2* allele ([@mjx004C20]; [@mjx004C40]; [@mjx004C11]). Significant differences between the *Mdm2*^*flox/+*^*αHoxb7-Cre* and control kidneys are seen during embryogenesis as early as E11.5. The phenotypic and morphological defects observed correlate with an increase in apoptosis in the ureteric bud branches at E14.5. The embryonic *Mdm2*^*flox/+*^*αHoxb7-Cre* kidney is riddled with apoptosis by E16.5. In addition to this, the mutant kidneys experience a decrease in cell proliferation, further explaining why they are underdeveloped. At postnatal day 1 (P1), *Mdm2*^*flox/+*^*αHoxb7-Cre* kidneys are visibly smaller and misshapen when compared to controls, and mice do not survive past weaning. The cortical and medullary areas of the mutant kidneys are indiscernible. Furthermore, the ureteric bud branches fail to extend the entire length of the kidney. All phenotypes are p53-dependent and can be rescued with concomitant loss of *p53*. More details on the roles of *Mdm2* and *Mdm4* specifically in the context of kidney development are published in an accompanying review by [@mjx004C500] in this special issue.

Eyeless mice {#mjx004s6}
============

Eye development is a precise process relying on tight regulation of multiple transcription factors. The ectoderm slowly thickens starting at E9.5 to form the lens of the eye. At this time, p53-mediated apoptosis, differentiation, and proliferation play crucial roles, implicating *Mdm2* and *Mdm4* in morphogenesis of the eye ([@mjx004C39]). The Lens*-Cre* (Le*-Cre*) transgene is used in combination with conditional alleles of *Mdm2* and *Mdm4* in order to remove these genes in the eye lens. The transgene begins expressing in the surface ectoderm around E9 and recombination is seen at E9.5. At E10, there are clear signs that the lens is unable to develop, progressing to E12.5 at which time a misshapen retina is all that remains in *Mdm2*^*FM/FM*^*Le-Cre* mice. Loss of *Mdm2* in the lens thus results in an eyeless *Mdm2*^*FM/FM*^*Le-Cre* mouse and neonatal lethality of unknown causes. Using the same genetic approach, loss of *Mdm4* also results in a viable eyeless *Mdm4*^*FX/FX*^*Le-Cre* mouse. The delay of the *Mdm4*^*FX/FX*^*Le-Cre* eyeless phenotype can be seen at E10.5, approximately an embryonic day later than *Mdm2*^*FM/FM*^*Le-Cre* mice. These data indicate that Mdm2 and Mdm4 play independent roles in development and maintenance of the lens structure.

The loss of *Mdm2* and *Mdm4* by Le-*Cre* increases p53 levels. TUNEL staining and BrdU incorporation are both notably increased signifying the increase in p53 function in *Mdm2* and *Mdm4*-deficient eye tissue. Notably, Pax6, a transcription factor highly expressed in eye development, does not show any significant differences following loss of *Mdm2* or *Mdm4* and thus, functions separately from the p53 pathway during lens organogenesis. Not surprisingly, all phenotypes of *Mdm2*^*FM/FM*^*Le-Cre* or *Mdm4*^*FX/FX*^*Le-Cre* mice are completely absolved through concomitant loss of *p53*.

Mdm2, but not Mdm4, is necessary for smooth muscle cell homoeostasis {#mjx004s7}
====================================================================

[@mjx004C3] wanted to determine whether non-cycling cells are dependent on p53 similar to rapidly proliferating cell types. They used a tamoxifen-inducible Cre-recombinase system in conjunction with either the floxed *Mdm2* or *Mdm4* allele in order to inactivate these genes specifically within the terminally differentiated smooth muscle cells (SMCs) of the intestine. This Cre is under the control of the *SM22* gene promoter, restricting its activity to the vascular and visceral SMCs of adult mice ([@mjx004C17]). *SM-CreER*^*T2*^*Mdm2*^*FM/FM*^ have significantly decreased body weights, are less responsive to stimuli, and develop hunched backs. Necropsies reveal a shortening and dilation of the small intestine. It is likely that the *SM-CreER*^*T2*^*Mdm2*^*FM/FM*^ mice die too quickly for additional significant pathologies to arise within these tissues---all mice are moribund between 8 and 11 days after the start of tamoxifen injections. Additionally, loss of *Mdm2* causes an elevation in the protein levels of p53 and its transcriptional activity in the affected tissues. Transcriptional targets, such as *p21*, are increased at the mRNA and protein level. Additionally, there is no evidence of increased apoptosis in the affected cells, showcasing that cell cycle regulation, but not cell death, is the key p53 stress pathway of SMCs after *Mdm2* loss. The phenotypes observed in *SM-CreER*^*T2*^*Mdm2*^*FM/FM*^ mice can be fully rescued through loss of *p53*. Unlike *Mdm2*, *Mdm4* is not essential for normal SMC homoeostasis in mice. Mice that lose *Mdm4* (*SM-CreER*^*T2*^*Mdm4*^*FX/FX*^) appear phenotypically normal compared to controls and show no signs of decreased functionality or increased p53 levels and activity.

Intestines bypass Mdm2 loss {#mjx004s8}
===========================

The epithelium of the intestines has the fastest cellular turnover taking between 24 and 60 h to repopulate the entire organ ([@mjx004C5]). Radiation of the intestine reveals that p53-dependent cell fate is determined by cell type. Undifferentiated cells are more sensitive to damage and thus apoptose, while differentiated epithelium has the ability to arrest.

To determine the significance of Mdm2 in regulating p53 in the intestinal epithelium, *Villin-Cre* was used ([@mjx004C33]). This gene is first active at E9 ([@mjx004C19]). Surprisingly, loss of *Mdm2* in the intestine leads to a viable mouse (*Mdm2*^*FM/FM*^*Vil-Cre* or *Mdm2*^*FM/−*^*Vil-Cre*). However, many early adverse phenotypes exist. These *Mdm2*^*FM/FM*^*Vil-Cre* mice display significantly lower body weights than their control littermates despite the fact that they are properly feeding and obtaining milk. This difference is apparent as early as P3. In addition, the intestines of these *Mdm2*^*FM/FM*^*Vil-Cre* mice show signs of inflammation as well as an increase in the intervillus pocket, indicating decreased absorption ability and abnormal tissue structure. Loss of *Mdm2* in the intestine leads to increased stabilization and activity of p53. In fact, the more severe the phenotype (smallest mice), the more p53-positive cells are present within the epithelium. Unexpectedly, no cell cycle arrest occurs despite an increase in mRNA levels of known cell cycle arrest-related p53 target genes. Surprisingly, with time, the intestinal epithelium of *Mdm2*^*FM/FM*^*Vil-Cre* mice selects against cells expressing *Cre* and regenerates the entire organ with cells that lack *Cre* and retain functional *Mdm2*. The intestinal epithelium increases proliferation of *Mdm2*-expressing cells and increases crypt fission events. This is dependent on intestinal stem cells, which also increase in number. As with other Mdm2 loss-of-function phenotypes, this too is rescued by *p53* loss.

The same Cre was used to explore loss of *Mdm4* in the intestinal epithelium (*Mdm4*^*FX/FX*^*Vil-Cre* or *Mdm4*^*FX/*Δ2^*Vil-Cre*) ([@mjx004C32]). This leads to a viable mouse with no obvious phenotypic differences throughout development and adulthood. However, there is an increase in p53 activity in the intestinal epithelium of these *Mdm4*^*FX/FX*^*Vil-Cre* mice, but it is confined to the highly proliferative areas. Similarly, staining reveals that apoptotic response in the intestine of these *Mdm4*^*FX/FX*^*Vil-Cre* mice is also confined to the highly proliferative cells after *Mdm4* loss. Additionally, *p21* is increased throughout the intestine despite the fact that the proliferation rate of these cells is not affected by the loss of *Mdm4*. In this cellular context, Mdm2 regulates p53 activity throughout the intestines, whereas Mdm4 only shows signs of p53 regulation specifically in the highly proliferative compartments.

Loss of Mdm2 in oocytes results in infertility {#mjx004s9}
==============================================

To determine whether Mdm2 and Mdm4 are implicated in the survival of oocytes during their development, a *Cre* gene driven by the *Zona Pellucida Glycoprotein 3* promoter (*Zp3-Cre*), which is exclusively expressed in growing oocytes, is used in conjunction with the conditional *Mdm2*^*FM*^ and *Mdm4*^*FX*^ alleles ([@mjx004C6]; [@mjx004C18]). Loss of *Mdm2* in the oocytes (*Mdm2*^*FM/−*^*Zp3-Cre*) leads to significantly decreased fertility, irregular menstrual cycling, and small ovaries. However, not all of the oocytes display the same phenotypes after loss of *Mdm2*. The authors hypothesized that the abnormal hormonal environment (high plasma follicle-stimulating hormone and luteinizing hormone coupled with low anti-mullerian hormone levels) and the resulted reproductive tract defects in the *Mdm2*^*FM/−*^*Zp3-Cre* mouse cause the fertility defects, not loss of *Mdm2* in oocytes. Crosses to *p53*-null mice rescue the phenotypes observed in the *Mdm2* knockout oocytes and restore fertility. Loss of *Mdm4* in oocytes (*Mdm4*^*FX/−*^*Zp3-Cre*) has no effect on fertility, hormone levels, nor show any morphological differences in the genital tract.

Global Mdm2 loss destroys normal tissues in adult mice {#mjx004s10}
======================================================

Since Mdm2 is the major negative regulator of p53, it has become an alluring therapeutic target for cancers that overexpress Mdm2 and remain WT for p53. However, these therapies are not tumour-specific and thus adverse effects of these drugs on normal tissues must also be explored. [@mjx004C38] addressed this question by conditionally removing *Mdm2* in a fully developed mouse (2--4 months old) using a tamoxifen-inducible *CAG-CreER* to recombine the *Mdm2*^*FM*^ allele in all tissue types. Tamoxifen injections were administered once a day for three consecutive days, and all *Mdm2*^*FM/−*^*CAG-CreER* mice in the study died within 2 days after the last tamoxifen injection. It is important to note that although all tissues experience recombination of the *Mdm2* allele, the degree of recombination is tissue-specific and does not directly correlate with the severity of the resulting phenotype.

Results indicate that both radio-sensitive and radio-insensitive tissues, such as the spleen and kidney, respectively, are negatively affected by the loss of *Mdm2*. Functional and morphological defects vary by age of the *Mdm2*^*FM/−*^*CAG-CreER* mouse and tissue type, yet all tissues experience some degree of perturbation of the p53 pathway shown through RT-PCR analysis of downstream targets. For example, after global *Mdm2* loss, there is an increase in protein casts and tubule dilation in kidneys of 4-month-old mice, whilst maintaining normal blood urine nitrogen (BUN) concentration. Normal BUN concentration signifies that the *Mdm2*^*FM/−*^*CAG-CreER* kidneys are still functioning properly despite significant morphological differences. Additionally, the kidney harbours the highest levels of p53 target genes, *p21* and *Puma*. Immunohistochemistry (IHC) reveals that p53 is stabilized in the kidney after *Mdm2* loss and apoptosis is evident. Conversely, the *Mdm2*^*FM/−*^*CAG-CreER* liver appears phenotypically normal compared to control tissues. However, the level of aspartate aminotransferase increases substantially, indicating that the livers of these mice are not functioning properly. The liver also stained positively for p53 and apoptosis after interrupted tamoxifen injections despite no dramatic increase in the mRNA levels of p53 target genes. Interestingly, the *Mdm2*^*FM/−*^*CAG-CreER* heart has no obvious morphological defects after acute *Mdm2* loss yet still shows significant increases in the mRNA levels of p53 target genes *p21* and *Puma*. Additionally, IHC does reveal changes in p53 protein levels. However, after prolonged exposure to *Mdm2* loss (through interrupted tamoxifen injections), fibrosis starts to show up in the heart. Increased exposure to Mdm2 loss causes stabilized p53 in addition to the morphological defects. Additionally, the same tamoxifen injections were given to year old mice. This study revealed that p53 activity was not as robust in older *Mdm2*-deleted mice.

Similarly, another group conducted analogous studies in which they globally explored p53 reactivation in *Mdm2-*null or *Mdm4-*null backgrounds ([@mjx004C28]; [@mjx004C8]). Both studies utilize the *p53*^*KI*/−^ mouse model that contains a p53-ER fusion. In the absence of tamoxifen, the *p53*^*KI*^ allele is functionally null (it should be noted however that *p53*^*KI/KI*^ mice do not rescue the *Mdm2-*null phenotype but *p53*^*KI/−*^ mice do). However, upon tamoxifen treatment, the WT p53 activity of this allele is restored. Thus, Mdm proteins are never present within these mice, and p53 activity is being toggled on and off by the presence or absence of tamoxifen injections. *Mdm2*^*−/−*^*p53*^*KI/−*^ mice exhibit similar defects to those found in the study of [@mjx004C38]. After the reactivation of *p53* through daily tamoxifen injections, these *Mdm2*^*−/−*^*p53*^*KI/−*^ mice only survive for up to 6 days. At that time, tissues were harvested for analysis. This group found that defects are seen in radio-sensitive tissues as early as 6 h after reactivation of WT *p53*. Not surprisingly, these *Mdm2*^*−/−*^*p53*^*KI/−*^ mice experience dramatic atrophy in radio-sensitive tissues such as the bone marrow, spleen (which lacks white pulp), thymus, small intestine, and colon (which has shortened villi). In addition, all of these tissues show dramatic upregulation in *p21* and *Puma* expression, and have numerous apoptotic cells. These mice also exhibit haematopoietic defects evident by an extreme reduction in all blood cell types.

Contrary to the Zhang study, radio-insensitive tissues experience fewer defects when utilizing the *p53*^*KI*^ allele. The *Mdm2*^*−/−*^*p53*^*KI/−*^ heart, liver, kidney, and brain all remain morphologically normal with no signs of increased proliferation or apoptosis. However, all tissues, especially the kidney and the brain, display elevated mRNA levels of *p21* and *Puma*, indicating that they are still affected by reactivation of *p53*.

*Mdm4* ^*−/−*^ *p53* ^*KI/−*^ mice surprisingly survive long past 1 week after p53 reactivation. Even with a continuation of tamoxifen injections, the median time of death is 29 days. This study reveals that lack of *Mdm4* is deleterious only in radio-sensitive tissues, not radio-insensitive. However, although the morphological defects and upregulation of *Puma* mRNA are limited to the bone marrow, spleen, thymus, and intestinal epithelium, all *Mdm4*^*−/−*^*p53*^*KI/−*^ tissues show upregulated *p21* mRNA. Thus, the only phenotypic differences seen are increased apoptosis in all radio-sensitive tissues as well as severe anaemia that is thought to lead to bone marrow failure resulting in the demise of these mice. The *Mdm4*^*−/−*^*p53*^*KI/−*^ liver, heart, kidney, and lung do not display any signs of apoptosis.

These studies exemplify the fact that radio-sensitive and radio-insensitive tissues are vulnerable to the loss of *Mdm2* (*Mdm2*^*−/−*^*p53*^*KI/−*^), while only radio-sensitive ones are vulnerable to *Mdm4* (*Mdm4*^*−/−*^*p53*^*KI/−*^), yet both result in the demise of mice due to unrestricted activity of p53. However, it is important to note that the results from the *p53*^*KI*^ allele are different from the genetic ablation of *Mdm2* due to the presence of only one copy of *p53*, which must be kept active by continuous tamoxifen injections. The tissue-specificity of unrestricted p53 activity must be explored further to better understand the differences observed in these studies.

Alterations in Mdm2 levels alone are sufficient to achieve deleterious unrestricted p53 affects {#mjx004s11}
===============================================================================================

Haploinsufficiency (50% of normal expression) of *Mdm2* or *Mdm4* leads to increased radiosensitivity due to defects in the haematopoietic system in a p53-dependent manner ([@mjx004C10]; [@mjx004C30]). The *Mdm2/Mdm4* double heterozygotes (*Mdm2*^*+/−*^*Mdm4*^*+/−*^) show defects in neural tube closure during development and have multiple organ defects. Furthermore, all blood cells are depleted in the double heterozygotes, though there is no sign of this in single heterozygotes (*Mdm2*^*+/−*^ or *Mdm4*^*+/−*^). Importantly, all of the double heterozygotes (*Mdm2*^*+/−*^*Mdm4*^*+/−*^) die within 20 days of birth, signifying the importance of the levels of these proteins in survival and proper development. All, however, are rescued by concurrent loss of one allele of *p53.*

[@mjx004C20] generated a hypomorphic allele for *Mdm2* (not *Mdm4*), which only expresses 30% of WT levels. These *Mdm2*^puro/Δ7--12^ mice are viable with defects in homoeostatic tissues. These mice have smaller body weights accompanied by small organs with those having the most significant decrease in size being the spleen and thymus. Not surprisingly, these *Mdm2*^puro/Δ7--12^ mice also have a poorly functioning haematopoietic system. They exhibit significant reduction of red blood cells, white blood cells, lymphocytes, T cells, and B cells compared to WT animals. Additionally, the lymphatic system of *Mdm2*^puro/Δ7--12^ mice shows twice the normal amount of apoptosis and an increase in p53 transcriptional targets, with *p21* experiencing the greatest upregulation. As expected, these mice also exhibit a p53-dependent increased sensitivity to IR.

Recently, another Mdm2 hypomorphic mouse (*Mdm2*^*PND/PND*^) was generated and identified due to increased pigmentation of its ears, tail, and paws ([@mjx004C24]). These mice express levels of *Mdm2* close to the threshold needed for survival; *Mdm2*^*PND/PND*^ mice are viable whilst *Mdm2*^*PND/−*^ mice are not. This mouse harbours a mutation in the P2 promoter in addition to a large deletion in intron 3 and retains a neomycin cassette. Thus, minimal levels of Mdm2 are being encoded solely from the P1 promoter. Characterization of these mice reveals high basal levels of canonical p53 targets expressed in spleens that increase upon radiation. Furthermore, *Mdm2*^*PND/PND*^ mice are extremely sensitive to radiation and die after exposure to 3-gray IR despite the fact that this is not immediately lethal for WT mice. Even without induced stresses such as IR, these *Mdm2*^*PND/PND*^ mice have shorter lifespans than WT controls, signifying that the prolonged increase in p53 is harmful.

Further phenotypic defects include weight differences in the *Mdm2*^*PND/PND*^ mice compared to WT controls at 1 year of age. Not only do the *Mdm2*^*PND/PND*^ mice weigh less in general, but they also have smaller hearts and testicles at 6 weeks of age. The small heart phenotype resolves itself by 1 year of age at which time they weigh the same as WT hearts. The reasons for the differences in heart weight are unknown, but the *Mdm2*^*PND/PND*^ mice do not seem to be negatively affected by the reduced heart weight during development. Despite some mice being fertile, the litter numbers are lower than expected, and the reproductive tracts of these mice are significantly smaller throughout their life and contain less germ cells resulting in breeding difficulties.

Not surprisingly, the haematopoietic system of the *Mdm2*^*PND/PND*^ mice is also altered. Blood count analyses reveal that both white and red blood cell counts in these mice are significantly lower than the WT age and sex-matched controls. The obvious dark pigmentation in these mice is coupled with spindled melanocytes and higher than normal melanin content. Furthermore, the pigmentation changes are specific to the epidermal layer; the dermis is indistinguishable from WT. This signifies clear tissue-specificity of *Mdm2* loss and *p53* hyperactivity, though the reasons for these phenotypic differences have not yet been determined.

Loss of one copy of *p53* is sufficient to alleviate the melanin hyperpigmentation and completely rescues the differences in weight and reproductive tract deficiencies of the *Mdm2*^*PND/PND*^ mice ([@mjx004C24]). Complete loss of *p53* was able to fully restore normal skin pigmentation. Moreover, to explore the tissue-specificity of downstream p53 targets, *p21-*null, *Puma*-null, and *p21;Puma* double null mice were crossed with *Mdm2*^*PND/PND*^ mice as attempted rescues. *p21*-loss decreases the severity of testes shrinkage, but does not rescue fertility nor does it alleviate any reproductive issues seen in *Mdm2*^*PND/PND*^ females, suggesting gender differences in sensitivity to hypomorphic *Mdm2*. *Puma*-loss completely rescues all reproductive shortcomings, resulting in normal litter numbers and sizes. The *Mdm2*^*PND/PND*^*p21*^*−/−*^*Puma*^*−/−*^ mice were generated in attempts to rescue the hyperpigmentation phenotype, after *Puma*-loss and *p21*-loss individually were unsuccessful. However, the double knockout also does not resolve the pigmentation alterations. Kit ligand (Kitl) is a downstream target of p53 that is involved in melanocyte migration, and *Kitl* mRNA levels are significantly upregulated in the *Mdm2*^*PND/PND*^ animals. However, removal of *Kitl* to determine whether melanocytes are able to return to normal is not possible due to the fact that Kitl inhibitors only affect melanocytes that have not yet migrated. Thus, inhibitors would have no effect on existing hyperpigmentation. It is important to note, however, that crossing the *Mdm2*^*PND/PND*^ mouse to a *Kitl* knockout mouse may successfully alleviate the skin pigmentation phenotype, but this has not been done.

Perspective and conclusions {#mjx004s12}
===========================

A large number of studies, summarized in this review, have probed the importance of Mdm2 and Mdm4 in a cell and tissue-specific manner. Regardless of the Cre driving deletion of *Mdm2*, *Mdm2* loss results in a cell lethal phenotype. For example, deletion in the heart results in cardiac defects that are lethal, deletion in the intestine results in compensatory repopulation of the intestinal epithelium with cells that express Mdm2, and global deletion of *Mdm2* in two different models results in a myriad of detrimental phenotypes that are lethal. All of these phenotypes are p53-dependent, further fortifying the role of Mdm2 as a major inhibitor of p53 activity.

*Mdm4* loss, on the other hand, is tolerated by many cell types but not all. During the highly proliferative embryogenesis process, *Mdm4* is required in the CNS during development, but not the heart for example. Interestingly, *Mdm4* loss is relatively well tolerated in many adult tissues. In all of these cases, the phenotypes are p53-dependent, emphasizing that too much p53 is detrimental to cell viability. It is the highly proliferative cells that appear to need both Mdm2 and Mdm4; perhaps because these cells need to dampen p53 levels quickly to allow developmental processes to proceed in a timely manner. The observation that disruption of the Mdm2--Mdm4 interaction is embryonic lethal further supports the idea that the Mdm2/Mdm4 heterodimer is the best p53 inhibitor during the highly proliferative embryogenesis process.

Studies of haploinsufficient and hypomorphic mice have further highlighted the need for Mdm2 in adult tissues. The haematopoietic system is a highly proliferative one that shows defects in many cases with slight decreases in Mdm2 levels. These studies, as well, have emphasized the need for increased levels of Mdm2 in response to damage. DNA damage increases p53 levels, and the basal levels of Mdm2 that exist in these mice are insufficient to return p53 to normal quickly enough, thus resulting in lethal phenotypes. The feedback loop-deficient mice are a perfect example of the need to make more Mdm2 to dampen p53 activities after DNA damage. These studies suggest that the relationship between Mdm2 and p53 is dynamic and changes with the needs of the cell.

Lacking is a real understanding of the p53 downstream effectors in a cell and tissue-specific manner. *Kitl* appears to be an important target in melanocytes and *Lif* in the uterus for implantation ([@mjx004C12]; [@mjx004C24]). *p21* is elevated 200-fold in kidneys upon *Mdm2* loss, the consequences of which are unknown. *Puma* deletion bypasses the fertility defects in *Mdm2* hypomorphic mice. An understanding of the factors implementing p53 function in a cell-specific manner may yield new therapeutic targets for reactivation of the p53 pathway in tumour development.

Since many cancers have high Mdm2 levels and WT p53, Mdm2 inhibitors have been developed and are now in clinical trials. Mdm2 inhibitors have yielded toxicities---the observed haematopoietic toxicities were predicted from mouse models as far back as 2003 ([@mjx004C20]). Another interesting observation that needs further exploration is the fact that *Mdm2* loss results in less p53 activity in older mice as compared to young mice. This difference may be exploited in treatment of older patients. While current therapies target Mdm2, *Mdm4* loss often displays less dramatic or deleterious effects, suggesting that Mdm4 may be a better therapeutic target due to its decreased toxicity. Clearly, additional studies are needed to understand the p53 signalling pathways upregulated upon *Mdm2* and *Mdm4* loss in a cell and tissue-specific manner.
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[^1]: Data include the Cre recombinase, whether a knock-in or transgenic model, the gene driver of the recombinase, tissue- or cell-specific site of expression, and initiation of expression. Additional information on these specific Cre-recombinase systems can be found in the attached cited works.
